ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

November 3, 1989

Conversation With The Cancer Letter: Ronald DePinho Says Moon Shots Will Go On

January 18, 2013

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

April 25, 2014

DeVita Changes Mind On OSP Phase Out Reasons, But Presses for “Internalizing” Coordinating Portfolio

January 1, 1988

Private Institute Commits $1 Million Pick Up some NIH Grants Left Unfunded

April 19, 1985

Cytopathologists, NCI Recommend New Method For Pap Smear Reports

August 25, 1989